IE64130B1 - Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder - Google Patents

Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Info

Publication number
IE64130B1
IE64130B1 IE92190A IE92190A IE64130B1 IE 64130 B1 IE64130 B1 IE 64130B1 IE 92190 A IE92190 A IE 92190A IE 92190 A IE92190 A IE 92190A IE 64130 B1 IE64130 B1 IE 64130B1
Authority
IE
Ireland
Prior art keywords
cycloserine
alanine
glycine
composition
treatment
Prior art date
Application number
IE92190A
Other languages
English (en)
Other versions
IE900921L (en
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of IE900921L publication Critical patent/IE900921L/en
Publication of IE64130B1 publication Critical patent/IE64130B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicinal Preparation (AREA)
IE92190A 1989-03-15 1990-03-14 Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder IE64130B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (2)

Publication Number Publication Date
IE900921L IE900921L (en) 1990-09-15
IE64130B1 true IE64130B1 (en) 1995-07-12

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
IE92190A IE64130B1 (en) 1989-03-15 1990-03-14 Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Country Status (17)

Country Link
US (1) US5061721A (cg-RX-API-DMAC10.html)
EP (1) EP0387867B1 (cg-RX-API-DMAC10.html)
JP (1) JP2963720B2 (cg-RX-API-DMAC10.html)
KR (1) KR900013961A (cg-RX-API-DMAC10.html)
AT (1) ATE88890T1 (cg-RX-API-DMAC10.html)
AU (1) AU624917B2 (cg-RX-API-DMAC10.html)
CA (1) CA2010635C (cg-RX-API-DMAC10.html)
DE (1) DE69001503T2 (cg-RX-API-DMAC10.html)
DK (1) DK0387867T3 (cg-RX-API-DMAC10.html)
ES (1) ES2055197T3 (cg-RX-API-DMAC10.html)
FI (1) FI901289A7 (cg-RX-API-DMAC10.html)
GR (1) GR3008225T3 (cg-RX-API-DMAC10.html)
IE (1) IE64130B1 (cg-RX-API-DMAC10.html)
IL (1) IL93562A (cg-RX-API-DMAC10.html)
NO (1) NO901198L (cg-RX-API-DMAC10.html)
NZ (1) NZ232809A (cg-RX-API-DMAC10.html)
PT (1) PT93424B (cg-RX-API-DMAC10.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP1060750B1 (en) * 1993-03-29 2005-12-07 Queen's University At Kingston Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
WO1998003541A1 (en) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokins
EP0964691A4 (en) 1996-07-22 2002-10-30 Cognetix Inc USE OF CONANTOKINE
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
DK1073432T3 (da) * 1998-04-14 2007-12-17 Gen Hospital Corp Anvendelse af D serin eller D alanin til behandling af skizofreni
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1383465B1 (en) * 2001-03-29 2011-08-10 Michael Davis Acute pharmacologic augmentation of psychotherapy with d-cycloserine
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1389181A4 (en) 2001-04-02 2005-10-19 Panorama Res Inc ANTIOXIDANT NITROXIDES AND NITRONES AS THERAPEUTIC AGENTS
WO2002087423A2 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
CA2478808A1 (en) * 2002-03-15 2003-09-25 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
KR20070104480A (ko) * 2003-05-27 2007-10-25 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2005014797A2 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
WO2005065308A2 (en) 2003-12-29 2005-07-21 Jason Mcdevitt Compositions and methods to treat recurrent medical conditions
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
ES2706063T3 (es) 2010-02-11 2019-03-27 Univ Northwestern Agonistas del receptor de NMDA y usos del mismo
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
ES2673956T3 (es) 2011-01-31 2018-06-26 Serotech, Llc Régimen de dosificación, envase de dispensación de la medicación y usos de los mismos para el tratamiento del trastorno depresivo mayor
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas
BR112015018089B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor de nmda de espiro-lactama, composição farmacêutica os compreendendo e uso dos mesmos
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP2951185B1 (en) 2013-01-29 2016-12-21 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
HRP20190613T1 (hr) 2013-01-29 2019-06-28 Aptinyx Inc. Spiro-laktam modulatori nmda receptora i njihove uporabe
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109415372B (zh) 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX388786B (es) 2016-08-01 2025-03-20 Aptinyx Inc Moduladores nmda espiro-lactam y métodos de uso de los mismos.
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
MX2022006342A (es) 2019-11-27 2022-08-11 Neurorive Inc Terapia combinada de cicloserina y litio para el tratamiento de la depresion.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
FI901289A7 (fi) 1990-09-16
CA2010635A1 (en) 1990-09-15
EP0387867B1 (en) 1993-05-05
JP2963720B2 (ja) 1999-10-18
IL93562A (en) 1996-01-31
AU5073490A (en) 1990-09-20
GR3008225T3 (cg-RX-API-DMAC10.html) 1993-09-30
IL93562A0 (en) 1990-11-29
JPH03148221A (ja) 1991-06-25
DE69001503D1 (de) 1993-06-09
EP0387867A1 (en) 1990-09-19
US5061721A (en) 1991-10-29
ATE88890T1 (de) 1993-05-15
DK0387867T3 (da) 1993-06-01
FI901289A0 (fi) 1990-03-15
PT93424A (pt) 1990-11-07
KR900013961A (ko) 1990-10-22
NZ232809A (en) 1992-05-26
CA2010635C (en) 2001-03-06
NO901198D0 (no) 1990-03-14
DE69001503T2 (de) 1993-09-09
PT93424B (pt) 1996-08-30
ES2055197T3 (es) 1994-08-16
NO901198L (no) 1990-09-17
AU624917B2 (en) 1992-06-25
IE900921L (en) 1990-09-15

Similar Documents

Publication Publication Date Title
CA2010635C (en) Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
AU622630B2 (en) D-cycloserine and its prodrugs as cognitive enhancers
US5260324A (en) Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
US5187171A (en) Use of a glycine b partial agonist as an antipsychotic
CA2153596A1 (en) Methods for the improvement of cognition with functional antagonists of the glycine nmda receptor complex
JP2023534189A (ja) Ｇａｂａａアルファ５アゴニストおよびｓｖ２ａ阻害剤の組合せ物ならびに認知障害の処置において使用する方法
US5087633A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5468763A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US6656962B2 (en) Use of amino-isoxazolidone compounds for improvement of lexical priming
US6962921B2 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
EP0689439B1 (en) Use of triazine compounds in the preparation of a medicament for the treatment of memory and learning disorders
JP2003221337A (ja) 酢酸アミド誘導体を有効成分とする痴呆症治療剤
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease
WO1996015787A1 (en) Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
JPWO2002010167A1 (ja) ２−アリール−８−オキソジヒドロプリン誘導体を有効成分とする痴呆症治療剤

Legal Events

Date Code Title Description
MM4A Patent lapsed